Meeting of the Board of Directors of the Company, duly convened and held at the registered office of the Company i.e. Plot No. 55, Office No. 104, First Floor, Vijay Block, Laxmi Nagar, ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Welcure Drugs & Pharmaceuticals met on September 2, 2025 and approved several items. Key decisions include: approving the Board's Report, Corporate Governance Report, and MD&A for FY ending March 31, 2025; increasing the threshold for loans, guarantees, and investments under Section 186 of the Companies Act; and raising the FPI/FII/FDI/NRI investment limit up to 49% of paid-up capital. The Board accepted the resignation of the existing statutory auditor, Chandabhoy & Jassoobhoy (effective August 21, 2025), and appointed M/s. Sarang Shivajirao Chavan & Associates as the new statutory auditor to fill the casual vacancy until the next AGM. CS Vishakha Agrawal & Associates was appointed as Secretarial Auditor for five years (FY2025-26 to FY2029-30). The 33rd AGM is scheduled for September 27, 2025 via video conferencing.
Shareholders should note the change in statutory auditor mid-year and the upcoming 33rd AGM on September 27, 2025. The increase in FPI/FII investment limit to 49% may broaden the pool of foreign investors but could also lead to higher volatility from foreign portfolio flows.